While GLP-1 receptor agonists lead today’s headlines, peptide therapeutics continue expanding across endocrine, oncology and imaging indications. Veloxity Labs keeps early-phase programs on schedule with peptide-savvy LC–MS/MS and phase-aligned documentation.
Our experienced team has supported hundreds of peptide programs—delivering the selectivity, sensitivity and speed sponsors need to advance confidently.